Back to Studies

Study analysis · Topics in Stroke Rehabilitation · 2026

Aerobic exercise boosts a key brain protein in stroke survivors—but the effect disappears within 6 months, and walking ability doesn't improve.

In a small trial, stroke patients who did 8 weeks of treadmill walking had an 18% relative increase in BDNF, a brain repair protein, but it didn't lead to better walking and the boost vanished after 6 months.

Reading level
Moderate certainty
Level 1b · Individual RCT

Overview

What the study found

The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.

In simple terms

This study is a randomized controlled trial, which is one of the best ways to test whether a treatment actually causes a change. It can show that the exercise program likely caused BDNF levels to go up right after training, but it cannot prove that this leads to better recovery after stroke.

What’s the bottom line?

In people who recently had a stroke, doing treadmill walking for 8 weeks increased levels of a protein called BDNF, which helps the brain heal. But the boost didn't last after they stopped exercising.

How strong is this study?

The study was well designed because people were randomly assigned to groups and the people measuring the results did not know who got which treatment. However, many blood samples were missing, the study was small, and participants knew which group they were in, so the results are not as strong as they could be.

Reporting

40 / 100

  • COI disclosure+40/40
  • Data availabilitydata not shared
  • Code availabilitycode not shared
Methodology

75 / 100

  • Randomization+20/20
  • Blinding+9/15
  • Control group+15/15
  • Sample size (n=67)+5.7/20
  • Follow-up+10/10
Publication

100 / 100

Statistical

100 / 100

  • P-values+15/15
  • Effect size+20/20
  • Confidence intervals+15/15
  • Pre-registration+15/15

Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.

Where it sits

RCT reviews

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Randomized Trials
Level 1b
79

79 / 100

Probability of being correct

Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.

This design can establish causation. The study is a randomized controlled trial, so it can support causal inference for the effect of the exercise intervention on serum BDNF in the short term. However, causation is limited to the biomarker outcome (serum BDNF) and cannot be extended to functional recovery after stroke. Confidence is reduced by the small sample size, substantial missing blood samples (33% loss), single blinding (participants and intervention providers not blinded), and a between-group confidence interval that crosses zero. The return of BDNF to baseline at 6 months also means the causal effect appears transient.

COI Unknown

Could not determine conflict of interest status

No conflict of interest or funding statement is present in the provided text, and all author affiliations are academic institutions. However, because the text appears truncated and lacks a formal declaration section, COI status cannot be fully assessed.

Independent Analysis Safeguards

  • Randomization by an independent researcher
  • Allocation concealment using numbered, opaque envelopes
  • Assessors blinded to group allocation
  • Analysis completed by researchers blind to group allocation
  • Prospectively registered trial (ACTRN12613000744752)

The provided text ends mid-sentence in the Methods section, so funding and conflict of interest declarations may be missing. Author affiliations are all academic institutions (University of Queensland, Australian Catholic University, University of the Sunshine Coast, Edith Cowan University), with no evident industry ties. No COI or funding information can be confirmed from the available text.

Key takeaways

  1. 01

    The exercise group's BDNF increased by 18% (relative) right after the program, then dropped by 18% (relative) six months later.

  2. 02

    The control group's BDNF didn't change much.

  3. 03

    Walking ability improved in both groups, but there was no extra benefit from the exercise program.

  4. 04

    The 18% relative increase was an absolute change of 5.3 ng/mL in BDNF levels.

  5. 05

    The study did not report how this affects stroke recovery or absolute risk of any outcome.

  6. 06

    The increase was temporary and did not lead to better walking ability.

Surprising findings

  • BDNF increase did not lead to improved gait performance.BDNF is thought to promote neuroplasticity and recovery, so many expected functional gains.
  • BDNF levels returned to baseline at 6 months despite continued higher physical activity in the intervention group (from parent trial).If exercise continues, one might expect BDNF to stay elevated, but intensity may have dropped.
  • Perceived exertion (BORG) correlated with BDNF increase, but maximum heart rate did not.Heart rate is an objective intensity measure, yet subjective effort was more predictive, possibly due to beta-blockers in 20% of participants.

Practical takeaways

For stroke survivors in rehab, consider adding moderate-to-high intensity aerobic exercise like treadmill walking (3x30 min/week) to boost BDNF.

The study was small, and the BDNF boost didn't improve walking ability in this trial. Effects fade if exercise stops.

Medium confidence

To maximize BDNF, aim for a higher total volume of exercise and push to a perceived exertion of 11-14 on the BORG scale (somewhat hard).

Correlational, not causal. Individual responses vary.

Low confidence

Don't rely on short-term exercise alone; maintain long-term physical activity to potentially sustain BDNF benefits.

The study didn't measure activity intensity during follow-up.

Low confidence

Why this study matters

The BDNF Boost That Doesn't Last

In 67 subacute stroke survivors, 8 weeks of moderate-to-high intensity treadmill walking increased serum BDNF by 18% relative (5.3 ng/mL absolute) compared to usual care (p=0.020). But by 6 months, BDNF levels had returned to baseline, dropping 18% relative (5.27 ng/mL absolute).

Many believe exercise-induced BDNF is a key mechanism for recovery, but this shows the effect is temporary and may require ongoing exercise to maintain.

No Gait Improvement Despite BDNF Increase

Despite the BDNF boost, the exercise group showed no significant improvement in walking speed (10MWT) or distance (6MWT) compared to usual care. Both groups improved over time, but the extra exercise didn't add benefit.

This challenges the assumption that increasing BDNF directly translates to functional recovery. It suggests other factors are at play.

More Exercise, More BDNF—But Intensity Perception Matters

Higher total treadmill distance and higher perceived exertion (BORG rating) correlated with greater BDNF increases (r=0.584, p=0.028 and r=0.542, p=0.045), but maximum heart rate did not. This suggests volume and how hard it feels may be key.

It gives patients a tangible target: walk more and push yourself to a moderate-hard effort.

First Study in Subacute Stroke—But Small and Leaky

This is the first RCT of aerobic exercise and BDNF in the subacute phase (within 2 months post-stroke). However, the study had a small sample (67) and 33% missing blood samples, limiting confidence.

It fills a gap but highlights the need for larger, more rigorous trials.

Want the whole report?

Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.

Standing

The people behind it

The researchers who wrote the study this analysis is built on.

Authored by

5 researchers

If this is your work, this is how we attribute it on Fit Body Science. Christopher P. Mackay is listed as the lead author.